Trends in the demographic and clinicopathological characteristics in Japanese patients with endometrial cancer, 1990–2010

Figures & data

Table 1 Demographic, clinicopathologic, and treatment trends

Characteristics	Decade A group (n = 116) (%)a	Decade B group (n = 203) (%)a	P-value
Age (year)			<0.001
<70	105 (90.5)	147 (72.4)
≥70	11 (9.5)	56 (27.6)
Parity			0.66
0	22 (19.0)	43 (21.2)
1–2	62 (53.4)	113 (55.7)
≥3	32 (27.6)	47 (23.1)
Body mass index			0.40
<25	83 (71.6)	136 (67.0)
≥25	33 (28.4)	67 (33.0)
Pelvic lymphadenectomy	99 (85.3)	170 (83.7)	0.24
Para-aortic lymph node sampling	39 (33.6)	103 (50.7)	<0.01
Median number of nodes (range)
Pelvic	14 (1–40)	13 (1–47)
Para-aortic	1 (1–7)	1 (1–14)
Positive lymph nodeb			0.88
Pelvic	12 (10.3)	12 (5.9)
Para-aortic	2 (1.7)	4 (2.0)
Pelvic and para-aortic	1 (0.9)	11 (5.4)
Surgical stagec			0.30
IA	71 (61.2)	109 (53.7)
IB	14 (12.1)	24 (11.8)
II	4 (3.4)	11 (5.4)
IIIA	7 (6.0)	19 (9.4)
IIIB	1 (0.9)	2 (1.0)
IIIC1	9 (7.8)	12 (5.9)
IIIC2	4 (3.4)	11 (5.4)
IV	6 (5.2)	15 (7.4)
Myometrial invasion			0.59
< 1/2	80 (69.0)	134 (66.0)
≥ 1/2	36 (31.0)	69 (34.0)
Histologyd			0.01
Endometrioid
Grade 1	59 (50.8)	88 (43.4)
Grade 2	32 (27.6)	45 (22.2)
Grade 3	13 (11.2)	26 (12.8)
Serous	6 (5.2)	24 (11.8)
Clear cell	1 (0.9)	7 (3.4)
Carcinosarcoma	5 (4.3)	13 (6.4)
Adjuvant chemotherapy	39 (33.6)	89 (43.8)	0.04
Adjuvant radiotherapy	5 (4.3)	7 (3.4)	0.70

Notes:

a Percent denotes proportion of patients during decade;

b cases with lymph node metastasis versus cases without lymph node metastasis;

c stages I and II versus stages III and IV;

d endometrioid versus serous carcinoma, clear cell carcinoma, and carcinosarcoma.

Figure 1 Kaplan–Meier analysis of cancer-specific survival stratified by decade.